Joe Kiwan is the latest ALADDIN student to join the 360 rotation programme at Sanofi.
Joe gained his BSc in Pharmacy at the Lebanese American University in Beirut, and is now studying for his Masters in Health Management and Data Intelligence at Emlyon Business School in Lyon. At the beginning of September 2024, he started his 6-month placement with Sanofi as part of the ALADDIN 360 Rotation Programme, which offers those working in the field of paediatric oncology the chance to work within the pharmaceutical and regulatory fields to gain an in-depth knowledge and understanding.
During Joe’s placement, he will be working within Sanofi’s paediatric oncology team, with three main objectives:
- To understand the execution of a clinical study
- To build a model for a paediatric study that shows how a drug interacts with the body
- To understand how Sanofi analyse their R&D pipelines for the childhood cancer programme
We look forward to seeing Joe’s progress over the next 6-months.
About the Rotation
6-month full-time placement at either Sanofi or Roche pharmaceutical companies involving a research project within their paediatric development teams and involvement in wider activities at the agency. Participants will be able to take a flexible working approach whilst completing the placement, with a combination of virtual and in-person working available.
- Participants at Sanofi can be located in either Paris (France) or Cambridge (UK)
- Participants at Roche can be located in either Basel (Switzerland) or Welwyn (UK)
The placement will be fully funded by the ALADDIN project under the EU Erasmus Programme.
The 360º rotation is open to applications from the following groups: Paediatric oncologist in late stages of training or an established investigator with a special focus on drug development.
-
- If still in training: Have finished a medical residency/specialty (paediatrics, medical oncology, clinical pharmacy, or other relevant specialties) and have completed at least 18 months of training in paediatric oncology.
- If an established investigator: Have a main research focus on paediatric oncology and a well-credited track of contribution to the field, with special interest in drug development.
Applications for Spring 2023 are now closed.
Who can apply?
